Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL13-PE38QQR in pediatric recurrent malignant glioma
NCT00053040Phase 2Withdrawn
- Sponsor
- Pediatric Brain Tumor Consortium
- Start
- Oct 2005
- Modality
- Immunotoxins, Fc-Fusion Proteins
01
Overview
Phase 2, open-label, single-arm trial of cintredekin besudotox in malignant glioma, sponsored by Pediatric Brain Tumor Consortium. Primary endpoints: Toxicities from the start of infusion through the dose limiting toxicity observation period at 75 days, Maximum safe flow rate at 70 days and 2 more. Planned start Oct 2005; status: withdrawn.
02
Drugs
cintredekin besudotox
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT00053040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00053040.